Oritavancin

Drug Profile

Oritavancin

Alternative Names: LY-333328; LY-333328 diphosphate; Nuvocid; ORBACTIV; Oritavancin diphosphate

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Eli Lilly
  • Developer The Medicines Company
  • Class Antibacterials; Glycopeptides; Peptide antibiotics
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Skin and soft tissue infections
  • Phase II Bacteraemia
  • Phase I Gram-positive infections
  • Preclinical Anthrax; Clostridium infections

Most Recent Events

  • 01 Apr 2016 The Medicines Company completes a phase I trial (In volunteers) in USA (IV) (NCT02471690)
  • 01 Jul 2015 The Medicines Company initiates enrolment in a phase I trial (In volunteers) in USA (NCT02471690)
  • 19 Jun 2015 The Medicines Company plans a phase I trial (In volunteers) in USA (NCT02471690)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top